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Introduction
Population-based surveys indicate that the 1-year
prevalence rate of migraine is 18.2% for women and
6.5% for men (1), indicating that about 30 million
people in the United States currently suffer from this
condition. Migraine is typically manifest by episodic
disabling headache lasting hours or days, with an
average attack frequency of one per month (2). Trip-
tans, the ergot alkaloids and non-steroidal anti-
inﬂammatory drugs (NSAIDs) are the three main
classes of drugs used to treat the pain and associated
symptoms of a migraine attack (3).
The US Headache Consortium recommends a
migraine-speciﬁc drug (triptan or ergotamine) for
patients with severe migraine or for patients whose
migraines respond poorly to NSAIDs or to combina-
tion analgesics (4). Several oral triptans (rizatriptan
10 mg, sumatriptan 100 mg and eletriptan 40–
80 mg) have been shown to have greater efﬁcacy
than ergotamines in double-blind randomised clinical
trials (5–7).
In randomised trials comparing different oral trip-
tans head-to-head, rizatriptan 10 mg appears to have
the greatest efﬁcacy (8,9). A large randomised clinical
trial (n ¼ 1268) reports signiﬁcant superior treat-
ment efﬁcacy of pain relief (PR) at 2 h and pain
freedom (PF) at 2 h after dosing for rizatriptan
10 mg over sumatriptan 100 mg (9). No differences
in PR and PF rates at 2 h are observed between riza-
triptan 5 mg and sumatriptan 100 mg (9). Using
freedom from pain 2 h after dosing as the outcome
measure, which is recommended by the International
Headache Society as the standard end-point for efﬁc-
acy measurement (10), rizatriptan 10 mg has greater
efﬁcacy than sumatriptan 25 mg, sumatriptan 50 mg,
sumatriptan 100 mg, naratriptan 2.5 mg and zolmi-
triptan 2.5 mg (8,11). In addition, patients taking
rizatriptan 10 mg report more proportions of 24-h
sustained PF rates than other oral triptans (8).
Overviews of placebo-controlled trials of individ-
ual oral triptans (12,13) indicate that rizatriptan
10 mg and eletriptan 80 mg exhibit placebo-subtrac-
ted values of PF at 2 h that are signiﬁcantly higher
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SUMMARY
Background: In the clinical trial setting, oral rizatriptan 10 mg has greater efﬁc-
acy than other oral triptans in freedom from migraine headache pain 2 h after dos-
ing. Objective: The study objective is to compare the effectiveness of rizatriptan
10 mg and other oral triptans for acute migraine attack in a naturalistic setting.
Methods: A total of 673 patients took rizatriptan 10 mg or their usual-care oral
triptans for two migraine attacks in a sequential, cross-over manner and recorded
outcomes using a diary and a stopwatch. Mean and median times to pain relief
(PR) and pain freedom (PF) for rizatriptan and other oral triptans were compared.
The effect of rizatriptan on times to PR and PF, adjusting for potential confounding
factors (treatment sequence, treatment order and use of rescue medication), was
computed via a Cox proportional hazard model. Results: Signiﬁcantly, more
patients taking rizatriptan achieved both PR and PF within 2 h after dosing than
other oral triptans. Times to PR and PF were shorter with rizatriptan than with
other oral triptans (median time to PR: 45 vs. 52 min, p < 0.0001; median time to
PF: 100 vs. 124 min, p < 0.0001). The adjusted proportional hazard ratios (rizatrip-
tan vs. other oral triptans) for times to PR and PF were 1.32 (95% CI: 1.22–1.44)
and 1.27 (95% CI: 1.16–1.39) respectively. Conclusion: The times to PR and PF
in a ‘naturalistic’ setting were signiﬁcantly shorter for patients treating a migraine
attack with rizatriptan 10 mg than with other oral triptans.
What’s known
Triptans are efﬁcacious migraine-speciﬁc therapy for
acute migraine. Rizatriptans, as compared with
other oral triptans, have shown greater efﬁcacy in
treatment outcomes.
What’s new
This article addresses an important question
whether rizatriptan 10 mg is more effective than
other oral triptans in aborting acute migraine in a
real-world setting. With regard to research
methodology, we strived for better measurement of
time to treatment end-points (using stopwatch
methodology) and minimising intra-patient
variations by adopting cross-over study design.
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whereas values of PF for other triptan dosages – al-
motriptan 12.5 mg, eletriptan 20 and 40 mg, nara-
triptan 2.5 mg, sumatriptan 25 and 50 mg,
zolmitriptan 2.5 and 5 mg – do not differ signiﬁ-
cantly from those for sumatriptan 100 mg (13).
It is unclear whether greater efﬁcacy in random-
ised clinical trials translates into greater effectiveness
in treating an acute migraine in a patient’s everyday
setting. Although there have been several open-label
naturalistic studies of triptans (almost invariably
rizatriptan) in comparison with patients’ usual treat-
ments, the ‘usual treatment’ comparator either non-
triptans (14–16) or combined triptans with other
non-triptan drugs (17). A recent open-label cross-
over trial reports that rizatriptan 10 mg has
enhanced PF rates at 2 h than almotriptan 12.5 mg
(18). No naturalistic study has focused on a compar-
ison of rizatriptan with other oral triptans, with time
to headache PF at 2 h as an end-point. The objective
of the current study is to investigate the effectiveness
of rizatriptan 10 mg compared with the oral triptans
usually taken by patients in a naturalistic setting.
Given the bioavailability differences exist among oral
triptans, comparison group was further categorised
into (1) other oral triptans (2), sumatriptan only (3),
fast-acting oral triptans (i.e. almotriptan, electriptan
and zolmitriptan), and (4) slow-acting oral triptans
(i.e. frovatriptan and naratriptan). The primary out-
comes were times to achieve PR and PF.
Methods
Study overview
The methods of this trial have been reported in
detail elsewhere (17). In brief, this was a multi-site,
prospective, open-label, two-migraine-attack, cross-
over study. Patients from across the United States
were recruited in their primary care physicians’
ofﬁces (see Appendix 1 for a list of participating
physicians). After providing informed consent, con-
secutive rizatriptan-naı ¨ve patients completed a base-
line questionnaire recording their demographic
characteristics, migraine history and the use of acute
and preventive migraine medications. Patients were
then provided with a take-home kit containing two
patient diaries, a stopwatch, two tablets of standard
formulation oral rizatriptan 10 mg, instructions for
data collection, and a stamped addressed envelope.
Patients were instructed to treat their next two
migraine attacks sequentially with either rizatriptan
10 mg or their usual migraine medication, in a
cross-over manner. The sequence of medication use
was left to the patient’s discretion. Patients were
asked to start the stopwatch upon taking the study
medication, and to record in the diary the time to
onset of PR and the time to PF. At the end of each
treatment diary, patients recorded how satisﬁed they
were with the prescription medication used to treat
their migraine. At the conclusion of the cross-over
phase, they were asked to indicate which acute
migraine medication they would prefer to use in
treating their next migraine. Patients treated their
migraines as they usually would, so that additional
prescription or over-the-counter medications were
allowed. The study protocol and all patient materials
used in this study were reviewed and approved by
Schulman Associates Institutional Review Board, Inc.
The study was carried out between September 2003
and February 2004.
Patients
Men and women were eligible to enter the study if
they were 18 years of age or older, had physician-
diagnosed migraine and a recent history of one or
more migraines per month, were rizatriptan-naı ¨ve,
had been prescribed an oral medication intended for
the acute treatment of migraine, and were ﬂuent in
English. The criteria for exclusion from the study
were pregnancy or any contraindication for the trip-
tans used in the study.
Outcome measures
The primary study outcome measures were the times,
in minutes, to migraine PR and PF, recorded by
stopwatch. Patients recorded these exact times in the
diaries provided in response to the questions ‘After
you took the ﬁrst prescription drug, how long did it
take before you started to feel onset of headache
relief, i.e. you felt that the drug started working?’
and ‘After you took the ﬁrst prescription drug, how
long did it take before you felt your headache was
completely gone?’ Secondary outcome measures were
patient satisfaction and patient medication prefer-
ence. Patient satisfaction was measured on a ﬁve-
point Likert scale (1, very satisﬁed; 2, satisﬁed; 3,
neither; 4, dissatisﬁed and 5, very dissatisﬁed) and
patient preference was evaluated in three categories
(1, rizatriptan; 2, other oral triptan and 3, no prefer-
ence).
Statistical analysis
This analysis is limited to patients whose previously
prescribed migraine medication was an oral triptan
(almotriptan, eletriptan, frovatriptan, naratriptan,
sumatriptan or zolmitriptan, but not rizatriptan) in
standard tablet formulation, and who used the stop-
watch provided to record the times to PR and PF.
The characteristics of patients who used rizatriptan
for their ﬁrst migraine attack and those who used
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and the statistical signiﬁcance of differences between
these two patient sets was determined using an inde-
pendent t-test for continuous variables and a chi-
squared test for proportions.
Times to PR and PF were analysed both as categ-
orical variables and as continuous. Comparisons were
made between the following groups: (i) rizatriptan
vs. all other oral triptans; (ii) rizatriptan vs. suma-
triptan only; (iii) rizatriptan vs. fast-acting oral trip-
tans (including almotriptan, electriptan and
zolmitriptan) and (iv) rizatriptan vs. slow-acting oral
triptans (including frovatriptan and naratriptan). For
categorical measurement of time, statistical signiﬁ-
cance of differences in proportion of patients achiev-
ing PR and PF within 2 h after dosing was evaluated
using McNemar’s test. For continuous measurement
of time, times to PR and PF were capped and cen-
sored at 3 days (i.e. 72 h or 4320 min) for patients
who either achieved PF beyond 3 days or did not
achieve PR and/or PF. The rationale of 3-day censor-
ing was chosen because most migraine patients
achieved PF within 3 days of attack. A paired t-test
was applied to test treatment differences (e.g. riza-
triptan vs. other oral triptans) in mean times to PR
and PF. As the distributions of times to PR and PF
were skewed, and parametric methods (which assume
a normal distribution) are not strictly valid, non-par-
ametric and semi-parametric methods were deemed
more appropriate. Median times to PR and PF were
presented by treatment groups, and the p-value asso-
ciated with the treatment comparison was obtained
from the Score Statistic in the Cox model, adjusting
for clustering.
Cox proportional hazards modeling was consid-
ered the appropriate tool for testing treatment differ-
ences in times to PR and PF. To account for the
clustering effect as a result of patients serving as their
own controls in this cross-over study, the Cox pro-
portional hazards model employed an independent
working assumption and used a robust sandwich
covariance matrix estimate. The variables controlled
for included treatment sequence, treatment order
and the use of rescue medications. Treatment
sequence was a dichotomous variable that measured
taking rizatriptan in the ﬁrst attack. Treatment order
was also a binary-coded variable that assessed the
numerical order of treatment sequence. Use of rescue
medication was coded as ‘1’ if an afﬁrmative
response was given to the question ‘Did you take any
non-prescription medication after you took their
prescription drug(s) to help relieve the migraine
attack?’ Patient satisfaction with rizatriptan in com-
parison with other oral triptans was evaluated in a
cumulative logit model, in which the dependent vari-
able was the satisfaction rating and the variables con-
trolled for included treatment sequence, treatment
order and the use of rescue medications. The pro-
portion of patients indicating their preference for
rizatriptan, other oral triptans and no preference was
described. All analyses were performed with SAS,
version 8. A p-value < 0.05 was considered to be sta-
tistically signiﬁcant.
Results
Patient sample
A total of 2368 patients were enrolled in the study.
Patients who did not follow the study protocol, who
did not use a stopwatch, or who did not use an oral
triptan as their comparator treatment were excluded,
so that 673 patients, with 1346 migraine attacks,
were included in the analysis presented here
(Figure 1). The excluded population had a statisti-
cally signiﬁcantly greater frequency of migraine-asso-
ciated vomiting (22.6% vs. 14.3%), diarrhoea (10.7%
vs. 6.2%) and blurred vision (32.5% vs. 26.5%).
Stopwatch users and non-users were similar in terms
of their educational levels, recent headache severity,
health insurance coverage and treatment sequence.
There were a slightly greater proportion of women
among stopwatch non-users (90.9%), than among
stopwatch users (83.4%).
The characteristics of the population included in
the analysis are presented in Table 1. The mean age
was 41.3 years, 83.4% were women, and the mean
age at ﬁrst diagnosis was 28.2 years. Patients’ ‘usual
care’ oral triptans were sumatriptan (49.6%), zolmi-
triptan (15.2%), eletriptan (13.8%), almotriptan
(11.7%), frovatriptan (5.1%) and naratriptan (4.6%).
A total of 386 patients (57.4%) used rizatriptan to
treat their ﬁrst migraine attack and 287 (42.6%) used
rizatriptan to treat their second migraine attack
(Table 1). There were no statistically signiﬁcant dif-
ferences between these two groups in age, gender,
age at ﬁrst diagnosis, migraine type, education,
recent headache severity, number of headaches in the
previous month or the use of rescue medications.
Times to pain relief and pain freedom
Proportions of achieving pain relief
within 2 h after dosing
Using the International Headache Society’s standard
treatment end-points, proportions of patients
achieved PR and PF within 2 h after dosing was
shown in Table 2. Signiﬁcantly more patients taking
rizatriptan (88.1%) achieved PR within 2 h after dos-
ing than patients taking other oral triptans (81.9%;
p ¼ 0.0003). Approximately nine of 10 patients
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n = 2,368
Protocol violations
n = 858
Non-triptan usual
care medication
n = 141
Did not use
stopwatch
n = 696
Lost to follow-up n = 462
Only one migraine n = 91
Non-crossover treatment n = 287
Non-protocol or unknown drug n = 18
Rizatriptan versus
other oral triptans
n = 673
Rizatriptan first
n = 386
Other oral
triptans first
n = 287
Figure 1 Patient sample
Table 1 Patient characteristics
Total (n ¼ 673)
Sequence
p-value
Took rizatriptan for
ﬁrst attack (n ¼ 386)
Took rizatriptan for
second attack (n ¼ 287)
Age, mean years (SD) 41.3 (11.5) 42.0 (11.4) 40.3 (11.6) 0.06*
Women (%) 83.4 81.8 85.6 0.19
Age at ﬁrst diagnosis, years (mean, SD) 28.2 (11.1) 28.6 (11.6) 27.7 (10.4) 0.29*
Migraine type (%)
Without aura 53.3 52.3 54.8 0.76
With aura 39.3 39.9 38.6
Other 7.3 7.8 6.6
Education (%)
Less than eighth grade 0.3 0.3 0.4 0.83
Some high school 3.9 4.2 3.5
High school graduate 24.3 22.6 26.7
Some college 29.7 29.4 30.2
College graduate 29.4 30.7 27.7
Postgraduate 12.3 12.9 11.6
Recent headache severity (%)
Mild 4.0 4.4 4.5 0.08
Moderate 45.2 48.7 40.1
Severe 50.6 46.9 55.4
Number of headaches in past month (mean, SD) 5.5 (5.6) 5.6 (5.7) 5.4 (5.4) 0.55*
Use of rescue medication (%)
None 86.4 84.9 88.4 0.18
Used for one attack 8.2 8.3 8.1
Used for both attacks 5.4 6.8 3.5
*t-test. Chi-square test.
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(87.1%) achieved PR within 2 h after dosing.
Patients taking rizatriptan disproportionately attained
PR within 2 h of dosing than patients taking either
fast- or slow-acting oral triptans.
Proportions of achieving pain freedom
within 2 h after dosing
With regard to PF, signiﬁcantly more patients taking
rizatriptan achieved PF within 2 h after dosing
(60.9%), than patients taking other oral triptans
(49.9%; p < 0.0001) (see Table 2). Across all sub-
group comparisons (i.e. sumatriptan, fast- and slow-
acting oral triptans), patients disproportionately
attained PF within 2 h after taking rizatriptan.
Mean and median times of pain relief
The mean and median times to PR by treatment
groups were displayed in Table 3a. The mean time to
PR was statistically signiﬁcantly shorter with rizatrip-
tan (87.2 min) than with other oral triptans
(162.3 min), a mean difference of 75.1 min (95% CI:
Table 2 Proportions of patients achieving pain relief and pain freedom within 2 h after dosing
Treatment groups
Achieved pain relief
within 2 h after dosing
Achieved pain freedom
within 2 h after dosing
% p-value* % p-value*
Rizatriptan (n ¼ 673) 88.1 0.0003 60.9 <0.0001
Other oral triptans (n ¼ 673) 81.9 49.9
Rizatriptan (n ¼ 334) 89.2 0.35 61.1 0.02
Sumatriptan (n ¼ 334) 87.1 54.2
Rizatriptan (n ¼ 274) 87.2 0.0011 59.1 0.0008
Fast-acting oral triptans (n ¼ 274) 78.1 47.1
Rizatriptan (n ¼ 65) 86.2 0.012 67.7 0.0007
Slow-acting oral triptans (n ¼ 65) 70.8 40.0
*McNemar’s test. Fast-acting oral triptans include almotriptan, electriptan and zolmitriptan. Slow-acting oral triptans include
frovatriptan and naratriptan.
Table 3 Treatment differences in times to pain (a) relief and (b) freedom
Treatment comparisons Mean (SD)
Mean differences
(95% CI) p-value*
Median
(95% CI) p-value
(a)
Rizatriptan (n ¼ 673) 87.2 (248.8) 75.1 (31.5–118.7) 0.0008 45 (40–45) <0.0001
Other oral triptans (n ¼ 673) 162.3 (546.9) 52 (45–60)
Rizatriptan (n ¼ 334) 90.0 (294.8) 20.3 ()27.2 to 67.7) 0.40 45 (40–45) 0.12
Sumatriptan (n ¼ 334) 110.3 (370.8) 45 (42–48)
Rizatriptan (n ¼ 274) 89.2 (211.5) 131.4 (46.9–215.9) 0.002 45 (40–45) <0.0001
Fast-acting oral triptans (n ¼ 274) 220.6 (702.9) 60 (48–60)
Rizatriptan (n ¼ 65) 64.2 (79.9) 119.3 ()13.9 to 252.6) 0.078 45 (40–45) 0.0003
Slow-acting oral triptans (n ¼ 65) 183.6 (538.3) 70 (60–90)
(b)
Rizatriptan (n ¼ 673) 261.5 (637.6) 96.8 (33.8–159.9) 0.003 100 (90–110) <0.0001
Other oral triptans (n ¼ 673) 358.3 (776.7) 124 (120–135)
Rizatriptan (n ¼ 334) 268.4 (689.8) 71.4 ()15.1 to 157.8) 0.11 100 (90–110) 0.009
Sumatriptan (n ¼ 334) 339.8 (798.3) 120 (112–128)
Rizatriptan (n ¼ 274) 279.9 (636.4) 93.2 ()12.9 to 93.2) 0.08 100 (90–110) <0.0001
Fast-acting oral triptans (n ¼ 274) 373.2 (767.3) 130 (120–147)
Rizatriptan (n ¼ 65) 148.2 (223.9) 242.9 (65.6–420.1) 0.008 100 (90–110) 0.006
Slow-acting oral triptans (n ¼ 65) 391.1 (709.3) 180 (120–210)
*Paired t-test. p-value was obtained from the Score Statistic of the Cox model, adjusting for patient clustering.
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tistically shorter for rizatriptan (45 min) than other
oral triptans (52 min, p < 0.0001). There was no sta-
tistical difference in mean or median times to PR
between rizatriptan and sumatriptan, although there
were some numeric advantages for rizatriptan.
Patients taking rizatriptan, as compared with either
fast- or slow-acting oral triptans, reported signiﬁ-
cantly shorter mean and median times to PR.
Mean and median times of pain freedom
The mean and median times to PF by treatment
groups were displayed in Table 3b. The mean time
to PF was statistically signiﬁcantly shorter with riza-
triptan (261.5 min) than with other oral triptans
(358.3 min), a mean difference of 96.8 min (95% CI:
33.8–159.9). Likewise, the median time to PF was
statistically shorter for rizatriptan (100 min) than
other oral triptans (124 min, p < 0.0001). Compared
with sumatriptan, patients taking rizatriptan reported
shorter median time to PF and similar mean time to
freedom. Patients taking rizatriptan, as compared
with either fast- or slow-acting oral triptans, reported
signiﬁcantly shorter mean and median times to PF.
Multivariate analyses
In the Cox proportional hazards model comparing
rizatriptan and other oral triptans (Table 4a), the
adjusted time to PR was 32% faster with rizatriptan
(hazard ratio 1.32, 95% CI: 1.22–1.44; p < 0.0001),
after adjusting for treatment sequence, treatment per-
iod and the use of rescue medications. The adjusted
time to PR was consistently faster with rizatriptan
than all other subgroup comparisons (i.e. sumatrip-
tan, fast- and slow-acting oral triptans).
Compared with other oral triptans (Table 4b), the
adjusted time to PF was 27% faster with rizatriptan
(hazard ratio 1.27, 95% CI: 1.16–1.39; p < 0.0001),
after adjusting for treatment sequence, treatment per-
iod and the use of rescue medications. The adjusted
time to PF was consistently faster with rizatriptan
than all other subgroup comparisons (i.e. sumatrip-
tan, fast- and slow-acting oral triptans).
Satisfaction and preference
A total of 668 patients completed the diary questions
about their satisfaction with their current medication
(Table 5). A greater proportion of patients indicated
that they were very satisﬁed when treating a migraine
attack with rizatriptan compared with other oral
triptans (29.5% vs. 19.5%). A smaller proportion of
patients reported that they were dissatisﬁed (12.3%
vs. 14.9%) or very dissatisﬁed (5.4% vs. 7.0%) when
treating a migraine attack with rizatriptan compared
with other oral triptans. In the cumulative logit mul-
tivariate model, patients were 52% more satisﬁed
when treating their attack with rizatriptan than when
treating with another oral triptan (odds ratio 1.52,
95% CI: 1.25–1.85; p < 0.0001), after adjusting for
treatment sequence, treatment order and the use of
rescue medications. Of the 652 patients, who
Table 4 Multivariate proportional hazards models of times to pain (a) relief and (b) freedom for rizatriptan relative to
other oral triptans
Treatment group comparisons Adjusted hazard ratio* 95% CI p-value
(a)
Rizatriptan vs. other oral triptans (n ¼ 673) 1.32 1.22–1.44 <0.0001
Rizatriptan vs. sumatriptan (n ¼ 334) 1.14 1.02–1.29 0.023
Rizatriptan vs. fast-acting oral triptans (n ¼ 274) 1.48 1.3–1.7 <0.0001
Rizatriptan vs. slow-acting oral triptans§ (n ¼ 65) 1.67 1.33–2.11 <0.0001
(b)
Rizatriptan vs. other oral triptans (n ¼ 673) 1.27 1.16–1.39 <0.0001
Rizatriptan vs. sumatriptan (n ¼ 334) 1.19 1.07–1.34 0.002
Rizatriptan vs. fast-acting oral triptans (n ¼ 274) 1.31 1.16–1.49 <0.0001
Rizatriptan vs. slow-acting oral triptans§ (n ¼ 65) 1.46 1.19–1.78 0.0003
*Adjusted variables included treatment sequence, treatment order and use of rescue medications. Chi-square test. Fast-acting oral
triptans include almotriptan, electriptan and zolmitriptan. §Slow-acting oral triptans include frovatriptan and naratriptan.
Table 5 Patient satisfaction with rizatriptan and with
other oral triptans
Rizatriptan,
n (%)
Other oral
triptans, n (%)
Very satisﬁed 197 (29.5) 130 (19.5)
Satisﬁed 253 (37.9) 277 (41.5)
Neither satisﬁed nor dissatisﬁed 100 (14.9) 114 (17.1)
Dissatisﬁed 82 (12.3) 100 (14.9)
Very dissatisﬁed 36 (5.4) 47 (7.0)
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tion preference, 304 (46.6%) expressed a preference
for rizatriptan, 220 (33.7%) preferred another oral
triptan and 128 (19.6%) expressed no preference.
Tolerability
One adverse event was reported by a 30-year-old
female patient who experienced hives and itchy skin
the day after taking rizatriptan. The symptoms subsi-
ded when treated with methylprednisolone. No other
adverse events were reported for rizatriptan.
Comment
This was a prospective, open-label, cross-over study,
in which patients took either oral rizatriptan 10 mg
or their usual-care oral triptans sequentially for two
consecutive migraine attacks, and timed the course
of their migraine pain using a stopwatch. Compared
with patients’ usual oral triptans therapy, the mean
time to PR was approximately 75 min shorter with
rizatriptan 10 mg, and the mean time to PF was
approximately 97 min shorter. Median times to PR
and PF were, respectively, 7 and 24 min shorter with
rizatriptan. Replicating the results in clinical trials, a
signiﬁcantly greater proportion of patients achieved
PR and PF within 2 h of dosing with rizatriptan than
with other oral triptans. The results of this naturalis-
tic study are consistent with those of double-blind,
randomised clinical trials, in which rizatriptan 10 mg
has equal or greater efﬁcacy for PF at 2 h postdose
than all other triptan dosages (8,9).
The extent to which rizatriptan is a more effective
acute migraine therapy than other oral triptans in a
naturalistic setting has not been reported. Rizatriptan
has previously been compared with patients’ usual
medications, which were either non-triptans or a
mixture of triptans and non-triptans. These studies
showed that rizatriptan had better treatment out-
comes than non-triptan medications (15,16). In a
study of the orally disintegrating formulation of riza-
triptan, the percentage of patients reporting PR and
PF at 2 h was more than twice as great with rizatrip-
tan as with patients’ usual, non-triptan medication
(15). In a pharmacy-based study comparing patients
who took rizatriptan with patients who took a non-
triptan, the percentage of patients reporting PR and
PF at 2 h was signiﬁcantly greater with rizatriptan
(16). The US Migraine Assessment Protocol study
compared rizatriptan 10 mg with patients’ non-trip-
tan usual medication (14,19). Signiﬁcantly more
patients were symptom free at 2 h after dosing with
rizatriptan than with patients’ usual treatment (19).
In studies in which the comparator included both
oral triptans and non-triptan, rizatriptan was again
found to have better treatment outcomes (17). In the
previous publication by Bell et al. (17), ‘usual treat-
ment’ included both triptan (80.6%) and non-triptan
migraine medications (19.4%). Not surprisingly,
when non-triptans were included in the usual treat-
ment, a greater treatment beneﬁt was observed with
rizatriptan: the mean times to onset of PR and PF
with rizatriptan compared to usual treatment were
85 vs. 107 min and 222 vs. 298 min respectively
(17). Our study reﬁnes Bell et al. analysis by compar-
ing rizatriptan with other oral triptans only. Consis-
tent with the existing literature of treatment in
naturalistic settings, we found that rizatriptan 10 mg
provided shorter times to PR and PF than other oral
triptans.
This report has made a number of improvements
in terms of study design, outcome measurement and
appropriate statistical analysis. Studies of triptans
employing pretest to post-test or parallel group
designs are vulnerable to certain biases. A pretest to
post-test design is vulnerable to temporal drift in
variables that might inﬂuence the results. A patient’s
migraine proﬁle may change spontaneously from one
attack to the next and changes in the migraine pro-
ﬁle may be attributed incorrectly to the effect of the
post-test intervention. In a non-randomised parallel-
group design, a patient selection bias may result in
non-comparable patient sets. The cross-over design
employed in this and other studies (14,17,19) is
meant to minimise these potential biases. A cross-
over design reduces intraperson variability, because
patients serve as their own controls. With this con-
trol for patient variability built into the study design,
one can more conﬁdently attribute differences in
outcomes to differences in the intervention rather
than to extraneous factors. With respect to the meas-
urement of the primary end-points, we strove to
time events precisely by asking patients to use a stop-
watch. Thus, in contrast to previous studies, which
categorised patients according to their pain status at
ﬁxed time points (14–16,19), we were able to docu-
ment events continuously in real time. Precise meas-
urement of the dependent variable enhances the
ability to detect differences between treatments.
Both times to PR and PF were not normally distri-
buted, but were skewed to the right, as a small pro-
portion (3.8–5.9%) of migraine patients were not
pain free 200 min after therapy (17). Mean times to
events may be more intuitive, but results derived
from means and parametric tests of statistical signiﬁ-
cance (e.g. t-test) may be inaccurate. In addition to
mean times to events, we reported median times
using semi-parametric (Cox proportional hazards
modeling) methods. Our ﬁndings that patients taking
rizatriptan for acute migraine had signiﬁcantly shor-
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oral triptans, were supported by statistical tests of
both mean and median time differences.
There are several caveats to the interpretation of
these results. For unknown reasons, a majority of
patients entering the study did not complete the pro-
tocol, introducing the possibility that the included and
excluded populations may not have been comparable.
We have noted that patients who were not included in
the analysis because of protocol violations had a statis-
tically signiﬁcantly greater frequency of migraine-asso-
ciated symptoms (17). In addition, there were a
slightly greater proportion of women among stop-
watch non-users (90.9%), than among stopwatch users
(83.4%). Our results, therefore, are only strictly
applicable to the migraine patients who followed the
research protocol and used a stopwatch to track their
time to headache events. Secondly, our deﬁnition of
PR was different from the one generally used in clin-
ical trials. In clinical trials, PR is typically deﬁned as a
reduction in headache pain severity from moderate/
severe to mild/none (10). In this study, we asked
patients to record the moment when they felt the onset
of headache relief. Although both deﬁnitions are sub-
jective, our deﬁnition may have exaggerated the degree
of PR. It is reasonable to assume that patients evalu-
ated their PR similarly whether taking rizatriptan or
other oral triptans. Any non-differential exaggeration
of PR would increase the noise in the estimation, thus
decreasing the chance of ﬁnding any statistically signi-
ﬁcant difference. Thirdly, the open-label study design,
in which patients were aware of the speciﬁc medica-
tions used for each attack, may have introduced a bias
between treatments, so that subjectivity and/or loyalty
to a particular brand name medication are potential
threats to validity. We attempted to control for this
type of artefact, by creating a numeric variable of the
order of treatment options and adjusting for its effect
in the multivariate analysis.
In conclusion, to the best of our knowledge, this
was the ﬁrst naturalistic study to compare rizatriptan
10 mg with other oral triptans using stopwatch
methodology. The study employed a multi-centre,
prospective, cross-over study design, with use of a
stopwatch to measure the primary study end-points
precisely. Rizatriptan was associated with shorter
times to PR and PF than were other oral triptans.
This study reproduced in a naturalistic setting the
results of double-blind, randomised clinical trials, in
which rizatriptan 10 mg has greater efﬁcacy in terms
of PF at 2 h postdose than the majority of other
triptan dosages. Patients were more satisﬁed with ri-
zatriptan than with other oral triptans and more
patients preferred rizatriptan than other oral triptans
for their next migraine attack.
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Appendix
Table 1 A list of participating physicians
Last name First name Title City State
Aaron Maureen MD Martinsville VA
Abdul-Wahab Muhammed MD Los Angeles CA
Absher John MD Greenville SC
Adams Quentin MD Arlington TX
Adkins Edward MD Mansﬁeld OH
Agrawal Anjula MD Washington DC
Alexander Michael MD Plantation FL
Alexandrova Natalia MD Arlington VA
Alhabian Oula MD Sylvania OH
Allen Chris MD Pittsburgh PA
Allen Thomas MD Overland Park KS
Alway David MD Alexandria VA
Andrews Roberta MD Macon GA
Andrus Dan MD Temecula CA
Ansell Jacqueline MD Northport AL
Anstadt David MD Warren OH
Anthony Jeff DO San Diego CA
Aoki Jeffrey MD Clovis CA
Arastu Jameel MD New Hartford NY
Arikawa Terry DO Granite Bay CA
Arkin Karen MD Overland Park KS
Auld Heather MD Fort Myers FL
Avanzato Joseph MD Yorktown Hgts NY
Avey Joseph MD Lehigh Acres FL
Awerbuch Gavin MD Bay City MI
Baier Charles MD Mandeville LA
Bailey-Walton Paula MD Beverly Hills CA
Baill Cori MD Orlando FL
Baker Keith DO Cape Coral FL
Ballenger Clarence MD Jacksonville NC
Barboza Beverly MD Los Gatos CA
Barrett Amelia MD Lonetree CO
Barrington Patricia DO Lawrenceville GA
Bartkowiak Anthony MD Altoona PA
Bartnick David MD Piqua OH
Bartos Paul MD North Canton OH
Bartos Sara MD Austin TX
Baurichter John DO Springﬁeld MO
Bayliss Robert MD Greenville SC
Baylor Melissa DO Dover PA
Beard Mary MD Salt Lake City UT
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Last name First name Title City State
Beck Brian DO Davison MI
Becker Jeffrey DO Scottsdale AZ
Becker Teresa MD Friendship TX
Beckert John DO Kahoka MO
Behm John MD Wexford PA
Belote Robert MD Leesburg VA
Benavides Angela MD Ottawa IL
Benchimol George MD Gainesville FL
Bennett Nathan MD Pittsburgh PA
Bennett Suzanne DO Phoenix AZ
Benzaquen Max MD Chesterﬁeld MO
Berriesford Gary MD Kingwood TX
Berriman Katherine MD Monroe OH
Bertrand V DO Frankfort IL
Bevers William MD Oklahoma City OK
Bhupalam Rukmaiah MD Louisville KY
Birk Harvinder MD Redding CA
Birkmann Lewiston MD Lincoln NE
Black Ross MD Cuyahoga Falls OH
Blady David MD Glen Ridge NJ
Blanchard Susan MD Mobile AL
Blank Benjamin DO Glendora NJ
Bloodworth James MD Greenville SC
Blume William MD Evansville IN
Bodemann Diane MD Hot Springs AR
Bodemann Stephen MD Hot Springs AR
Bolinger Jony MD Easley SC
Borsheim Mark MD Hayden Lake ID
Boulware William MD Florence SC
Bowhay Thomas MD Jackson CA
Brandstater Cherry MD Redlands CA
Braun Edward MD Tampa FL
Breitenbach Ray MD Waterford MI
Bressler Jill MD Englewood Cliffs NJ
Brewer Raymond MD Universal City TX
Brodsky Hal MD Gainesville FL
Brooks Mark MD Anderson Island WA
Brown Carl DO Odessa TX
Brown David MD Fayetteville AR
Brown Morris MD Dayton OH
Brown Raymond MD Cleveland TN
Brown Thomas MD San Antonio TX
Brown William MD Tyler TX
Bryan Angela MD Cape Coral FL
Burnette Thomas MD Brewster NY
Butler-Sumner Susan MD Cave Spring GA
Buynak Robert MD Portage IN
C Quaglieri Frank MD Reno NV
Cagle Mary MD Greenville SC
Calise Paul MD Ft Lauderdale FL
Calland Ann DO Westerville OH
Cameron Daniel MD Mount Kisco NY
Campbell James DO Broken Arrow OK
Carlini Walter MD Medford OR
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Last name First name Title City State
Carmichael Patrick MD Gainesville FL
Carter John MD Tucson AZ
Castaldo John MD Allentown PA
Castor Terrance MD Worthington OH
Cavalier Steven MD Baton Rouge LA
Cerbone Tracey MD Port Saint Lucie FL
Cevasco Robert MD Medina OH
Chamikles Jason DO Middle Vlg NY
Chan Kahing MD Opelika AL
Chan Kenneth DO Jonesboro AR
Charani Kimy DO Tucson AZ
Charney Jonathan MD New York NY
Chehrenama Mahan DO Alexandria VA
Chequer Rosemary MD Lancaster CA
Chessin Vicki MD Alma MI
Clark James MD Provo UT
Clemens Michael MD Palm Harbor FL
Clendening Marilyn MD North Canton OH
Conard Scott MD Irving TX
Cook Charles DO Bedford TX
Cook Jolanda MD Abihgdoh VA
Cooley Richard MD Baton Rouge LA
Cooper Kirsten MD Stanley NC
Costa Ralph MD Voorhees NJ
Costin Scott MD Bellefontaine OH
Cottingim Gary MD Greenville SC
Counce Diane MD Alabaster AL
Crabtree Yvette MD Mission KS
Craig William MD Greenville SC
Crawford Edgar MD Portland OR
Crosnoe Janna MD Cape Girardeau MO
Crump William MD Chicago IL
Csepany Emerico MD Cerritos CA
Cuellar James MD Wentzville MO
Cushman Kenneth MD Tyler TX
Czulada Gary DO Dover PA
Davis David MD Fayetteville AR
Davis Lloyd MD Des Plaines IL
De Armitt Don MD Harrisburg PA
De Garmo Ronald DO Greer SC
De Haven Joseph MD Savannah GA
De Santis Michael MD Hickory NC
Debin Susan MD Orange CA
Decker Andrew MD Yorktown Hts NY
Delp Robert MD Clawson MI
Deyarmin Brian MD Bethel Park PA
Dibert Steven MD Gastonia NC
Doehring Larry DO Northglenn CO
Doghramji Paul MD Pottstown PA
Doran Anne MD Midlothian VA
Doreshow Larry DO Philadelphia PA
Dougherty Richard MD Charlotte NC
Dougherty Nancy MD Portland OR
Downey Kathleen MD Cincinnati OH
Drake Alan MD Sparta TN
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Drake Robert MD Somerset KY
Dresser Lee MD Newark DE
Drinnen Jeffrey MD Knoxville TN
Druzak Karen MD Naperville IL
Dugan Thomas MD Monaca PA
Dugano-Daphnis Pamela MD League City TX
Dumbacher Perri MD Lake Mary FL
Duncan Garcia Stephanie DO Coral Gables FL
Dure-Smith Belinda MD San Diego CA
D’ Cruz A MD Lubbock TX
Ebersole Philip MD Temecula CA
Eck Jeffrey MD Elkhart IN
Edelmann Karl MD Ann Arbor MI
Elder Robert MD Hartsville SC
Elkind Arthur MD Mount Vernon NY
Ellis Brian MD Melbourne FL
Ellis Paul MD Alpharetta GA
Emerson Russell MD Stanley NC
Englert Jack MD Huntsville AL
Enns Richard MD Huntington Beach CA
Entin Erik MD Plainview NY
Eppinette James MD West Monroe LA
Erbay Celal MD Gainesville FL
Eshenaur Oliver DO Orrville OH
Eslami Nasrollah MD Chicago IL
Esposito Anthony MD Anniston AL
Estrada-Massey Adahli MD Auburn AL
Eubank Geoffrey MD Columbus OH
Evans Bryan MD Huntsville AL
Fahey Patricia MD Englewood CO
Fason Jeff MD Florissant MO
Feldman Ludmila MD Staten Island NY
Fesler William MD Bartlesville OK
Fields Carolyn MD Greenville SC
Fife Terry MD Scottsdale AZ
Finch John DO Seattle WA
Fink Alan MD Wilmington DE
First Brian MD San Diego CA
Fischer Calvin DO Hoffman Estates IL
Fisher Robert MD Fort Smith AR
Fisher Tobin MD Huntsville AL
Fisher Todd MD Middletown PA
Flechas Jorge MD Hendersonville NC
Fleming Frank MD Greenville NC
Fleming Peter MD Watertown MA
Fleshman Daniel MD Hilliard OH
Flitman Stephen MD Phoenix AZ
Ford Don MD Sugar Land TX
Ford Jack MD Colorado Spgs CO
Forner Stephen MD Chico CA
Foster Carol MD Phoenix AZ
Fox Kenneth DO Levittown PA
Franklin Michael MD Saint Petersburg FL
Freberg Daniel DO Mesa AZ
Friedman Aaron MD New Orleans LA
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Friedrich Brian DO Drexel Hill PA
Friend Harold MD Boca Raton FL
Fritz John DO Jersey City NJ
Fullemann Susan MD Burlingame CA
Fung Wilson MD Santa Clarita CA
Furey William DO Stratford NJ
Gaddis Kenneth MD Thibodaux LA
Gaikwad Shilpa MD Oxnard CA
Gardner Jack MD Dallas TX
Gardner Raymond MD Mansﬁeld OH
Garg Ram MD Woodhaven MI
Garrett David MD Bentonville AR
Gatiwala Indravadan MD Lumberton NC
Gaya William MD Ocala FL
Gebel Michael MD Winter Park FL
Gehi Chandra MD Anniston AL
Gerard William DO Milwaukee WI
Gervais Donald MD Houma LA
Gill Naurang MD Woodbridge VA
Gilson Paul MD Brick NJ
Glapinski Robert DO Capac MI
Glasser Michael MD New York NY
Gluckman Richard MD San Pedro CA
Goering Edward DO Portland OR
Goldberger Daniel MD Portage MI
Goldstein Gary MD Palm Harbor FL
Golnick Jan MD Omaha NE
Golub Bari MD Saint Louis MO
Gordon Colette MD Chicago IL
Gordon Norman MD E Providence RI
Gosling John MD Clinton MI
Govindan Srini MD Wheeling WV
Graff Justin MD Belden MS
Grass David MD Fairfax VA
Graves Christy MD Slidell LA
Graves Kurt MD Baton Rouge LA
Green Phillip MD Kalamazoo MI
Greenberg William MD Saint Petersburg FL
Greenblatt Lawrence DO Bellevue WA
Greenwood John MD Lenexa KS
Greg Zoltani John MD Tacoma WA
Gregg Hardy J MD Greenville NC
Grellet Catherine MD Los Gatos CA
Grimball Roger MD Sulphur LA
Griner Donald DO Mesa AZ
Grote Stewart DO Lansing KS
Grover Daniel MD Greenville SC
Guin Johnson Darlene MD Oklahoma City OK
Haga Edward MD Hampton VA
Hallmark Belton MD Castle Rock CO
Halper-Erkkila Ruby MD White House Station NJ
Halpern Betty MD Houston TX
Halverson James DO Newport News VA
Hamo Wael MD Sylacauga AL
Hanley Patricia MD Austin TX
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Hanley Thomas MD Voorhees NJ
Hanrahan Beth MD Clearwater FL
Hanson James MD Waukesha WI
Hantos Livia MD Buffalo Grove IL
Hare Ester MD Orangeburg SC
Harris Mark MD Atlanta GA
Harrison Stephen MD Fulton IL
Harvey Frank MD West Carthage NY
Hatharasinghe Roger MD Statesville NC
Head Gilbert MD Omaha NE
Hegde Hemant MD Ogden UT
Henderson Reggie MD Lexington TN
Henson Lois DO Vandalia OH
Hernandez Rafael MD Fredericksbrg VA
Herrold James MD Boise ID
Hiebert Pamela MD Bozeman MT
Hilgeman Joseph MD Manchester MO
Hirsch Jeffrey MD Oklahoma City OK
Hoffman Daniel MD Dunlap IL
Holleman Kevin MD Portage MI
Holt William DO Port Charlotte FL
Homan James DO Tampa FL
Hosso-Cooper Jennifer DO Oak Lawn IL
Hostetter Carol DO Westerville OH
Howard Jerome MD Charlotte NC
Howe Jeffrey MD Elkhart IN
Howe Steve DO Marietta OH
Howell Gregory MD Ocala FL
Hrabarchuk Eugene MD Franklin NJ
Hsu Jui MD Elkton MD
Huddlestone John MD Chicago IL
Hudson Ronald MD Columbus GA
Hunt Wade MD New Hartford NY
Husain Mohammad MD Valley Stream NY
Husid Marc MD Augusta GA
Hutchison Edward MD Brea CA
Inamine Gary MD Honolulu HI
Ireland Cliff DO Skokie IL
Isenberg-Rawls Judy MD Madison AL
Ivy Mary MD Lititz PA
Izzo Timothy DO Grand Ledge MI
J Holladay Dawnetta MD Athens GA
Jackson Rebecca MD Knoxville TN
Jacobus Brent DO Crown Point IN
Jao Kedy DO La Mirada CA
Jeffries Nancy DO Ephrata PA
Jenckes George MD Reading PA
Jirovec Richard MD Lincoln NE
Johnson Constance MD Clarksville TN
Johnson James MD Greenville SC
Johnson Mark MD Salt Lake Cty UT
Johnson Michael MD Bucyrus OH
Johnson Michael MD Sherwood OR
Jones Helen MD Fresno CA
Joshi Sanjeev MD Chicago Hts IL
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Jurcik Yvonne MD Buffalo Grove IL
Justiz William MD Naples FL
Kafka Christopher DO Gladstone MO
Kagan Jeffrey MD Newington CT
Kailasam Jayasree MD Houston TX
Kalahasthy Annadorai MD Dayton OH
Kalra Arun MD Monroe LA
Kaplan Ryan MD Fayetteville AR
Karimi Kambiz MD Indianapolis IN
Kaville Robert MD Scranton PA
Keehbauch Jennifer MD Orlando FL
Keinarth Paul MD Austin TX
Kelemen John MD Plainview NY
Keller David MD Hershey PA
Kelsey Alan MD White House Station NJ
Kent Robert DO Arlington TX
Kersting Clayton MD Newport WA
Kessler Thomas MD Mobile AL
Khalid Aijaz MD Columbus GA
Kiefer Peter MD Des Plaines IL
Kilo Charles MD Naples FL
Kingston Caroline MD Santa Fe NM
Kipp Joseph MD Newtown PA
Kiser Roy MD Richardson TX
Kistler Charles DO Columbus OH
Klein Jeffrey MD Westlake Vlg CA
Knight Rebecca MD Peoria IL
Knipfer Mark MD Spartanburg SC
Knubley William MD Fort Smith AR
Koch Stanley MD Morton IL
Koffman Brian MD Diamond Bar CA
Koopman Anton MD Columbus IN
Kopp James MD Newport News VA
Kordish Theresa DO Kalamazoo MI
Kovacevic Olga MD Strongsville OH
Kovacs Suzanne MD Spartanburg SC
Kristl Kevin MD South Bend IN
Kritz David MD Orange CA
Krupitsky Andrew DO Altamonte Spg FL
Krusz John MD Dallas TX
Kumar Ansuya MD Plano TX
Kumar Seema MD Alexandria VA
Kunst Edward MD Manchester MO
Kurlander Ronald MD Pompano Beach FL
Kurtzer Yitzchok MD Scranton PA
Kurzawa Mark MD Clinton Township MI
Kwon-Hong Grace MD Modesto CA
Laeger Jane MD Bangor ME
Lamb Chad MD Anderson IN
Lambert Lise MD Ft Lauderdale FL
Larrison Charles MD Hot Springs AR
Lazarus Kenneth MD Fayetteville GA
Ledet Michael MD Mobile AL
Lee Daniel MD Greenville NC
Lee Kang MD Ludington MI
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Lee Keung MD Asheboro NC
Leeds Leroy MD Houston TX
Leitman Jeffrey DO Stratford NJ
Leitzinger Linda DO Erie PA
Leland Richard MD Greenville SC
Lele Anju MD Mentor OH
Lele Geeta MD Hobbs NM
Lele Shreeniwas MD Mentor OH
Levin Kenneth MD Ridgewood NJ
Lewison Gary MD East Dundee IL
Liebentritt Matthew MD Longmont CO
Lieux Theodore MD Baton Rouge LA
Lillo Joseph DO Scottsdale AZ
Lim Andrew MD Wakeﬁeld MA
Lin Cheng-Te MD Lima OH
Lindholm Karin DO Chicago IL
Lindley Mark MD Plymouth MI
Lipscomb Geoffrey MD Foley AL
Lisgar Harvey DO Richboro PA
Loftus Brian MD Houston TX
Look Michelle MD San Diego CA
Lucas Cynthia NP Macon GA
Lum Katharine MD Vero Beach FL
Luria Eric MD Gig Harbor WA
Lynn Lon DO Tampa FL
Ma Sherry MD Saint Louis MO
Magpile Michael MD La Mesa CA
Magre Ann-Marie MD Fayetteville AR
Maida Gerald MD Bloomingdale IL
Majid Abdul MD Menasha WI
Manning Rickey MD Knoxville TN
Mannix Lisa MD Westchester OH
Marlow Robert MD Huntsville AL
Marmel Richard MD San Antonio TX
Marquino Rey MD Dennison OH
Marraccini Linda MD Miami FL
Martin John MD Edmond OK
Mathew Ninan MD Houston TX
Matthews Dale MD Washington DC
Maurides Peter MD Greenville SC
Mauskop Alexander MD New York NY
May James MD Shreveport LA
Mayer David DO Huntsville AL
Mc Carren Timothy MD Cincinnati OH
Mc Carthy Christopher MD Saint Louis MO
Mc Clain David MD American Fork UT
Mc Daniel Gregory MD Youngstown OH
Mc Ghee Terrence MD Asheville NC
Mc Lean-Bennett Jacquelyn DO Albany NY
McCallum Gary MD Bellingham WA
Mcphee Robert DO Crystal River FL
Melton Gary MD Crittenden KY
Menachem Allan MD Whiteville NC
Mentock Sabrina MD Durham NC
Michel Elliot MD Natrona Hts PA
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Michelsen Thomas DO Jacksonville FL
Miller Michael MD Chesterland OH
Miller Roger MD Jacksonville FL
Miller Tamara MD Fort Collins CO
Millermaier Edward MD Portage MI
Millermaier Janet MD Portage MI
Mills Richard MD Mount Pleasant SC
Mingione Donald MD Portsmouth VA
Mir Sarim MD Cumberland MD
Moberly Harold MD Winchester KY
Mockler Karen MD Dadeville AL
Modi Smita MD Iselin NJ
Mogle Douglas MD Melbourne FL
Molter Darron MD N Myrtle Bch SC
Monje Marile MD Crystal Lake IL
Moon Steven MD Fayetteville AR
Moore Harold MD Columbia SC
Moore Terrence MD Denton TX
Moran Joseph MD Statesville NC
Morrill Thomas DO Garland TX
Morse Michael MD Fayetteville AR
Mueller Nancy MD Englewood Cliffs NJ
Mullowney James DO Mesquite TX
Munshower John MD Marcus Hook PA
Murillo George MD Tomball TX
Murphy Ann DO Overland Park KS
Murphy Duffy MD Logansport IN
Muse Derek MD Salt Lake Cty UT
Nakano Kenneth MD Kailua HI
Naples Robert DO Cortland OH
Natrajan Puthugramam MD Augusta GA
Navarro Evelyn MD Grand Rapids MI
Nayyar Manmohan MD Apple Valley CA
Nazario Liliana MD Overland Park KS
Neely Kathryn MD Canton GA
Nelson Robert MD Norco CA
Nestor Gregory MD Saint Petersburg FL
Newman Stephen MD Plainview NY
Ng Ken MD Ocala FL
Nieves Alfredo MD Chattanooga TN
Norman Howard DO Avondale AZ
Norys James MD Fayetteville AR
O’Carroll Christopher MD Newport Beach CA
Odio Alberto MD Simi Valley CA
Ohashi Gary MD Westminster CA
Olson Michael MD Sioux Falls SD
Ondrejicka John MD Jacksonville Beach FL
Oppy James MD Connellsville PA
Osio Antonio MD Wichita KS
Ottley Barbara-Jean MD Hays KS
Owusu-Yaw Victor MD Danville VA
Paley Judith MD Denver CO
Palmer Madelyn MD Littleton CO
Parcells Patrick MD Newport News VA
Pare Bernard MD Mount Juliet TN
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Park Richard MD Universal Cty TX
Parker David DO Northglenn CO
Parker Richard DO San Diego CA
Parmer Keith MD Rome GA
Parsley Donna DO Pickerington OH
Patel Alpa MD Jacksonville FL
Patel Mrugendra MD Richlands VA
Patterson Brian MD Bellingham WA
Paul Alan MD Tyler TX
Payne Richard MD Encinitas CA
Peacock Mark MD Jacksonville FL
Pearlman Eric MD Savannah GA
Peggy Jones Mary MD Tucson AZ
Perdikis George MD Lancaster CA
Perel Allan MD Staten Island NY
Perlman Neil MD Vernon Hills IL
Perry William MD Centre AL
Pham Khoi MD Aurora CO
Phelan James MD Kingwood TX
Pierce Paul MD Vicksburg MS
Pillow Deborah MD Addyston OH
Polyhronopoulos Spiro MD Lebanon KY
Porter Andrew MD Gilbertsville KY
Posgai Scott MD Orlando FL
Potts Gregory MD Louisville KY
Prater Fredric DO Saint Louis MO
Pratt Joseph MD Corinth MS
Prince Vickie MD Jacksonville FL
Pugach Neil MD Chesapeake VA
Putland Kenneth MD Newport News VA
Quick Robert MD Crete NE
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